Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population
, , and
Jun 21, 2023
About this article
Article Category: Research Article
Published Online: Jun 21, 2023
Page range: 211 - 219
Received: Nov 27, 2022
Accepted: Dec 26, 2022
DOI: https://doi.org/10.2478/raon-2023-0019
Keywords
© 2023 Cvetka Grasic Kuhar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
FIGURE 2.
Clinical characteristics of participants at beginning of the study and after one-year post-chemotherapy
| Tumour stage | ||
| T1 | 6 (45.1) | 32 (44.4) |
| T2 | 43 (42.2) | 33 (45.8) |
| T3 | 13 (12.7) | 7 (9.7) |
| Lymph node stage | ||
| N0 | 43 (42.2) | 31 (43.1) |
| N1 | 38 (37.3) | 30 (41.7) |
| N2 | 12 (11.8) | 9 (12.5) |
| N3 | 9 (8.8) | 2 (2.8) |
| Tumour subtype | ||
| Luminal A-like | 12 (11.8) | 7 (9.7) |
| Luminal B-like | 47 (46.1) | 35 (48.6) |
| Luminal B HER2 positive | 19 (18.6) | 14 (19.4) |
| HER2 positive | 8 (7.8) | 6 (8.3) |
| Triple-negative | 16 (15.7) | 10 (13.9) |
| Type of surgery | ||
| Breast-conserving surgery + Sentinel node biopsy | 37 (36.3) | 28 (38.9) |
| Breast-conserving surgery + Axillary dissection | 14 (13.7) | 11 (15.3) |
| Mastectomy + Sentinel node biopsy | 23 (22.5) | 15 (20.8) |
| Mastectomy + Axillary dissection | 28 (27.5) | 18 (25.0) |
| Breast reconstruction | ||
| None | 78 (76.5) | 55 (76.4) |
| Deep inferior flap | 13 (12.7) | 10 (13.9) |
| Tissue expander, followed by silicone implant | 11 (10.8) | 7 (9.7) |
| Chemotherapy type | ||
| Anthracyclines and taxanes | 70 (68.7) | 51 (70.8) |
| Anthracyclines only | 19 (18.6) | 13 (18.1) |
| Taxanes only | 10 (9.8) | 6 (8.3) |
| CMF | 3 (2.9) | 2 (2.8) |
| Anti-HER2 therapy | 27 (26.4) | 20 (27.8) |
| Adjuvant endocrine therapy | 78 (76.5) | 57 (79.2) |
| Radiotherapy | 81 (79.4) | 59 (81.9) |
Patient-reported outcomes presented by EORTC C30 Summary Score (C-30 SumSc) and global health status/quality of life (GHS) at inclusion (beginning of chemotherapy), one-year post-chemotherapy, and the difference among both times
| n | mean | Mean (95% CI) | p | Mean (95% CI) | p | Mean (95% CI) | p | |
| C-30 SumSc | 70 | 90.9 | 88.5 (86.1, 90.8) | 0.04 | 82 (78.4, 85.5) | < 0.001 | −6.5 (−9.6, −3.4) | < 0.001 |
| GHS | 71 | 72.7 | 71.1 (66.7, 75.6) | 0.50 | 69.6 (65, 74.2) | 0.19 | −1.5 (−6.6, 3.5) | 0.55 |